Adverse events with fatal outcome
Best Practice Nordic | Sept 2019 | | ECTRIMS 2019
Sporadic cases of fatal adverse events have been reported during treatment of multiple sclerosis with alemtuzumab. In this MEDtalk Trygve Holmøy present a study based on European Medicines Agency database of suspected adverse reactions related to medicinal products in the European Economic Area (EudraVigilance), for fatal adverse events associated with treatment with alemtuzumab. Trygve Holmøy and colleagues identified nine cases with a probable and one case with a possible causal relationship between alemtuzumab treatment and a fatal adverse event.